CHP/PCOR Publications

Benefits vs Profits: Has the Orphan Drug Act Gone Too Far?

Journal Article

Author
Alan M. Garber - Stanford University

Published by
Pharmacoeconomics, Vol. 5, page(s) 88-92
1994

Publications of interest

Creating the Costliest Orphan: The Orphan Drug Act in the Development of Ceredase
AE Clarke, DP Goldman, Alan M. Garber
International Journal of Technology Assessment in Health Care vol. 8 (1992)
Pills, Profits and Politics
Philip R. Lee, M Silverman
University of California Press (Berkeley) (1974)
Is Having More Preapproval Data the Best Way to Assure Drug Safety?
Alan M. Garber
Health Affairs vol. 27, 5 (2008)
Evidence Suggesting that Health Education for Self Management in Chronic Arthritis Has Sustained Health Benefits while Reducing Health Care Costs
KR Lorig, PD Mazonson, Halsted Holman
Arthritis and Rheumatism vol. 36 (1993)

The Benefits and Costs of Health Plan Choice: The Case of Medicare Part D Prescription Drug Plans
M. Kate Bundorf
Do You Get What You Pay For? The Relationship Between Premiums and Benefits in Medicare Prescription Drug Plans
Kosali Simon
HIV in Russia: The Cost-Effectiveness of Treating Injection Drug Users with Antiretroviral Therapy
Elisa Long
Assessing the Costs and Benefits of Screening for HIV
Swati Tole, DK Owens